hotspot -WSS

hotspot

author：leisure time 2025-10-01 00:47:05 - browse：3

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Colonoscopy prep: Liquid

explore

WSS

Gene editing the human germline: What are the risks?

Asbestos, a deadly carcinogen, banned by EPA

Virtual Event: March of the Biosimilars

Study: Why relieving medical debt did not improve financial outcomes

AstraZeneca to buy developer of next

Nurses recount patients attacks

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Gene editing the human germline: What are the risks?

BioMarin wins approval for gene therapy to treat hemophilia A

Stop the failed accountable care organization experiment

Supreme Court strikes down use of affirmative action

Medical device trials still don't enroll enough women, study finds

At least 13 dead in Texas as scorching temps continue

ALS patient reclaims some autonomy thanks to wearable 'robot'

United colonoscopy coverage change 'may cost lives,' doctors say

Coercive sterilizations revealed by STAT prompt outrage

knowledge

Intermittent fasting comes with a heart risk? Not so fast

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Teladoc has a new CEO, but challenges remain the same

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Positive childhood experiences can help future health

SCOTUS questions limit to govt efforts to fight misinformation

focus

explore

explore

Wikipedia